Aprea Therapeutics (APRE) shares jumped Wednesday after the company released encouraging preliminary data from its ongoing Phase 1 trial of APR-1051, a WEE1 kinase inhibitor designed to treat advanced cancers.

What the Data Shows

The trial produced a second unconfirmed partial response in a patient battling advanced endometrial cancer. Target lesion measurements shrank by 50%, which is exactly the kind of result you want to see in early-stage cancer trials. Even more encouraging, the patient's CA-125 tumor biomarker levels plummeted from 362 U/mL at baseline down to 47 U/mL. That's a dramatic drop that signals real anti-tumor activity.

Aprea continues enrolling patients in the 220 mg dose cohort and plans to broaden the study to include additional patients with specific genetic alterations. The trial is designed to evaluate both safety and efficacy of APR-1051, with more comprehensive updates expected in the second quarter of 2026.

What Analysts Think

The stock currently holds a Buy Rating from analysts. Recent actions include Wedbush maintaining an Outperform rating while lowering its price target to $7.00 on February 10, and HC Wainwright & Co. keeping a Buy rating but dropping its target to $4.00 on January 29.

Price Movement: Aprea shares climbed 16.62% to $0.70 at the time of publication Wednesday.